UB Paderborn / Katalog / Suche / in CDI

Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Journal of clinical oncology, 2006-08, Vol.24 (22), p.3562-3569

2006

Link zum Volltext

Verfügbarkeit prüfen

Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.2020-2026

2008

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Therapeutic advances in medical oncology, 2022-01, Vol.14, p.17588359221141307-17588359221141307

2022

Link zum Volltext

Verfügbarkeit prüfen

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

The lancet oncology, 2022-11, Vol.23 (11), p.1367-1377

2022

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Journal of clinical oncology, 2018-03, Vol.36 (7), p.674-681

2018

Link zum Volltext

Verfügbarkeit prüfen

Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic

British journal of cancer, 2021-11, Vol.125 (11), p.1486-1493

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT-13-05: Dolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCBG308)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-13-05-OT-13-05

2021

Link zum Volltext

Verfügbarkeit prüfen

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients

European journal of cancer (1990), 2017-03, Vol.74, p.98-108

2017

Link zum Volltext

Verfügbarkeit prüfen

Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer

Cancer research (Chicago, Ill.), 2009-06, Vol.69 (11), p.4700-4707

2009

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

European journal of cancer (1990), 2020-09, Vol.136, p.25-34

2020

Link zum Volltext

Verfügbarkeit prüfen

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.15-15

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort

Future oncology (London, England), 2021-09, Vol.17 (25), p.3343-3353

2021

Link zum Volltext

Verfügbarkeit prüfen

Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice

Breast (Edinburgh), 2019-04, Vol.44, p.39-45

2019

Link zum Volltext

Verfügbarkeit prüfen

Logistic Regression Model of the Clinical Response to 5-Fluorouracil Based Chemotherapy for Metastatic Colorectal Cancer Patients

Anticancer research, 2006-09, Vol.26 (5B), p.3885-3892

2006

Link zum Volltext

Verfügbarkeit prüfen

Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions

Pathology oncology research, 2020-10, Vol.26 (4), p.2469-2473

2020

Link zum Volltext

Verfügbarkeit prüfen

Lymph Node Assessment with 18F-FDG-PET and MRI in Uterine Cervical Cancer

Anticancer research, 2011-11, Vol.31 (11), p.3865-3871

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3534-3534

2016

Link zum Volltext

Verfügbarkeit prüfen

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3531-3531

2016

Link zum Volltext

Verfügbarkeit prüfen

Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer

Anticancer research, 2011-11, Vol.31 (11), p.3865-3871

2011

Link zum Volltext

Verfügbarkeit prüfen

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3541-3541

2015

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Toxicity with Capecitabine, Vinorelbine and Trastuzumab Therapy: Case Report and Review of Fluoropyrimidine-Related Cardiotoxicity

Oncology, 2009-04, Vol.76 (5), p.322-325

2009

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Multicenter Study of Optimal Circadian Time of Vinorelbine Combined with Chronomodulated 5-Fluorouracil in Pretreated Metastatic Breast Cancer Patients: EORTC Trial 05971

Chronobiology international, 2008-01, Vol.25 (5), p.680-696

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic

Abstract OT-13-05: Dolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCBG308)

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients

Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer

DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study

Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort

Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice

Logistic Regression Model of the Clinical Response to 5-Fluorouracil Based Chemotherapy for Metastatic Colorectal Cancer Patients

Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Lymph Node Assessment with 18F-FDG-PET and MRI in Uterine Cervical Cancer

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer

Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial

Cardiac Toxicity with Capecitabine, Vinorelbine and Trastuzumab Therapy: Case Report and Review of Fluoropyrimidine-Related Cardiotoxicity

A Randomized Multicenter Study of Optimal Circadian Time of Vinorelbine Combined with Chronomodulated 5-Fluorouracil in Pretreated Metastatic Breast Cancer Patients: EORTC Trial 05971

Suchergebnisse filtern